Ocular angiogenesis, or the abnormal growth of blood vessels in the eye, is the cause of major neovascular eye diseases. In addition, retinal and choroidal neovascularization are the major causes of vision loss in this country. With the new era of anti-angiogenic therapies already in practice, ophthalmologists have started treating many ocular diseases including macular degeneration, diabetic retinopathy, and retinal vascular occlusion using anti-angiogenic drugs.
Therapy for Ocular Angiogenesis: Principles and Practice covers the basic pathophysiology of ocular angiogenesis and strategies for inhibition. The authors discuss the Principles of anti-angiogenic therapy, pre-clinical studies, future drugs on the horizon, drug delivery, and the Practice of the therapy in many ocular diseases. Vision researchers in both academia and industry, as well as clinician scientists, have contributed chapters on different aspects of the angiogenic process, and clinical strategies to fight it. The book also includes chapters that deal with diabetic macular edema, and various therapeutic options for this condition.
A companion website includes the fully searchable text and an image bank.
--Discusses the principles of angiogenesis therapies and pathophysiology of
--Summarizes the clinical trials that led to approval of two FDA approved drugs in the field.
--Discusses ongoing clinical trials in the field.
--Describes potential new anti-angiogenesis drugs in the horizon.
--Discusses different drug delivery approaches in the eye.
Table of Contents
1: Tumor Angiogenesis: Concept
Judah Folkman (Reproduction of the Hellen Keller Foundation Lecture 2006)
2: Retinal Neovascularization: Pathophysiology
3: Choroidal Neovascularization: Pathophysiology
4: VEGF the Major Player
5: IFG-1 in Angiogenesis
6: Is It All the VEGF? Other Factors
7: Proteinases and Integrins
Alexander Ljubimov and Arup Das
8: Endogenous Inhibitors
9: Macular Edema: Molecular Mechanisms
1: Anti-VEGF Therapies in ARMD in Practice
2: Novel Anti-VEGF Drugs in ARMD Currently in Trials
3: Safety of Anti-VEGF Drugs
David Boyer and Thomas Friberg
4: Pharmacokinetics of Anti-VEGF Drugs
5: Anti-VEGF Therapies of Retinal Neovascularization
6: Anti-VEGF Therapies in Diabetic Macular Edema
7: Steroids in ARMD and Macular Edema
8: Anti-VEGF Therapies in ROP
9: Pharmacotherapy in Retinal Vein Occlusions
10: Intravitreal Injection: Technique and Complications
11: Role of OCT in Management of ARMD and Macular Edema
12: Role of Laser in the Era of Pharmacotherapy
13: PDT: Is It an Option?
14: Combination Therapy: Future
15: Gene Therapy in Ocular Angiogenesis
16: Stem Cell Therapy
17: Drug Delivery in Posterior Segment: Challenges
Prithvi Mruthyunjaya and Glenn Jaffe
18: Corneal Neovascularization
19: Neovascular Glaucoma
20: Financial Impact of Anti-Angiogenic Therapy
21: Future of Anti-Angiogenic Therapy
Arup Das MD, PhD
Professor of Ophthalmology, University of New Mexico, Albuquerque, NM
Thomas Friberg MS, MD
Professor of Ophthalmology, The Ear and Eye Institute of Pittsburgh, Pittsburgh, PA